Group purchasing organization Vizient reported a 610 percent boost in demand from June 16-19, the period just after preliminary study results suggested dexamethasone — an inexpensive steroid often used to treat asthma, arthritis and some cancers — could improve mortality rates among the sickest COVID-19 patients.
The rate at which drugmakers could fill dexamethasone orders and send them to hospitals dropped from 97 to 54 percent by June 19, according to Vizient.
More articles on pharmacy:
Ramping up US drug production: 3 obstacles to consider
APhA launches task force, #PharmacistsFightingRacism campaign
Sanofi expedites its vaccine timeline, strikes $2.3B deal with Translate Bio
